A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00000998

Enrollment

Registered

2001-08-31

Start date

Unknown

Completion date

1989-04-30

Last updated

2021-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia, Pneumocystis Carinii, HIV Infections

Keywords

Trimetrexate, AIDS-Related Opportunistic Infections, Pneumonia, Pneumocystis carinii, Injections, Intravenous, Leucovorin, Dose-Response Relationship, Drug, Drug Therapy, Combination, Folic Acid Antagonists, Administration, Oral, Acquired Immunodeficiency Syndrome, Antineoplastic Agents

Brief summary

To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug which is effective for treatment of PCP, but has been given to only a few patients. Therefore it is not certain if TMTX is better, the same as, or not as effective as conventional drugs against PCP.

Detailed description

TMTX is an experimental new drug which is effective for treatment of PCP, but has been given to only a few patients. Therefore it is not certain if TMTX is better, the same as, or not as effective as conventional drugs against PCP. Increasing doses of TMTX are used in combination with LCV as initial treatment for PCP in 50 AIDS patients. Doses are increased for 21 days on a once daily and then a twice daily basis. Dose escalations occur in subsequent groups of patients.

Interventions

DRUGTrimetrexate glucuronate

DRUGLeucovorin calcium

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

Patient must: * Have Pneumocystis carinii pneumonia (PCP) that has not been treated for current episode. PCP must be documented by observation of \> 1 cluster of organisms in sputum, bronchial secretion, or lung tissue. * Have clinical symptoms of respiratory disease or radiologic abnormalities.

Exclusion criteria

* Patient cannot have significant emotional disorder. Concurrent Medication: Excluded: * Drugs likely to be bone marrow toxic. * Investigational drugs. Prior Medication: Excluded: * Three patients in each group cannot have had zidovudine (AZT) for at least 2 months prior to administration of trimetrexate.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026